Skip to main content
. Author manuscript; available in PMC: 2012 Sep 1.
Published in final edited form as: Mol Cancer Ther. 2011 Jun 23;10(9):1698–1708. doi: 10.1158/1535-7163.MCT-11-0107

Figure 5.

Figure 5

E3330 pharmacokinetic profile and analysis of tumor growth rate in PaCa-2 and patient-derived xenografts. A, Serum concentrations of E3330 following one dose at 25 mg/kg, ip in 9% DMSO; B, Serum concentrations of E3330 (25 mg/kg, ip, 9% DMSO) following dosing at 0-h and 8-h as indicated by the arrows. C, Tumor growth delay following treatment with E3330 in PaCa-2 xenografts (left) and patient-derived tissue, Panc253 (right).